This study examines how **maridebart cafraglutide** affects heart health in people with atherosclerotic cardiovascular disease (ASCVD) who are also overweight or obese. ASCVD occurs when arteries thicken due to plaque, which can lead to heart attacks or strokes. **Maridebart cafraglutide** is a medication tested alongside regular treatments to see if it can better prevent heart issues compared to a placebo, which is a harmless pill with no active medicine. **Eligibility:** Participants must be 45 years or older, have a Body Mass Index (BMI) of 27 or above, and a history of ASCVD. People with recent serious heart events, certain diabetes conditions, or specific medical histories cannot join. **Key Points:** - **Study Length:** The study will require attending several visits over a period of time. - **Compensation:** Participants might receive compensation for their time and travel. - **Risks:** Possible side effects from the medication or placebo, similar to any medical study. Before joining, consider the time commitment, potential benefits, and risks. Always discuss with a healthcare provider to ensure it is suitable for you.